Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Neuromuscular weakness and Duchenne muscular dystrophy

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Neuromuscular respiratory or bulbar failure

Weak cough, drooling, choking, inability to count or speak normally, orthopnoea, morning headache, paradoxical breathing or rapid loss of mobility can precede hypoxaemia and requires urgent ventilatory assessment.

Action: Use ABCDE, measure serial respiratory function when feasible, avoid excessive oxygen without ventilation assessment, involve paediatric intensive care and neuromuscular teams and protect swallowing and airway clearance.

Synopsis

Localise childhood weakness, identify respiratory and bulbar emergencies, recognise Duchenne muscular dystrophy early and organise creatine kinase, genetic confirmation, corticosteroid, cardiac, respiratory and family care.

  • Localise weakness by onset, proximal or distal distribution, symmetry, fatigability, reflexes, sensation, cranial and bulbar signs and upper motor-neurone features.
  • Duchenne muscular dystrophy usually becomes apparent between two and five years with delayed milestones, Gowers manoeuvre, waddling, toe walking, falls and calf pseudohypertrophy.
  • First-line testing for a boy with unexplained motor delay or proximal weakness is serum creatine kinase; a very high result demands urgent neuromuscular referral, not repeated observation.
  • Confirm dystrophinopathy with molecular genetic testing, starting with methods that detect exon deletions or duplications and then sequencing when required; biopsy is reserved for unresolved cases.
  • A normal newborn period does not exclude Duchenne, and language or learning difficulty may precede obvious weakness because dystrophin isoforms are expressed in brain.
  • Corticosteroids prolong ambulation and preserve respiratory and upper-limb function; the neuromuscular team selects daily or intermittent prednisolone or deflazacort and monitors toxicity.
  • Cardiac surveillance begins before symptoms and uses ECG plus echocardiography or cardiac MRI; cardioprotective therapy is introduced through the specialist protocol.
  • Serial forced vital capacity, sleep study when indicated, cough assessment, vaccination and assisted cough or non-invasive ventilation prevent crisis better than waiting for resting hypoxaemia.
  • Avoid succinylcholine and alert anaesthesia to dystrophinopathy because hyperkalaemic arrest and anaesthesia-associated rhabdomyolysis can occur.
  • Offer genetic counselling, carrier testing through clinical genetics, education support, bone protection, physiotherapy, psychosocial care and timely transition as one coordinated pathway.

Key red flags

Loss of previously acquired motor skills, rapid progression or weakness after a normal early course requires urgent neurological assessment.

Weak cough, recurrent aspiration, sleep-disordered breathing, morning headache or inability to lie flat suggests respiratory muscle failure even with normal oxygen saturation.

Duchenne clues include delayed walking, Gowers manoeuvre, frequent falls, waddling gait, toe walking and calf enlargement in a preschool boy.

Markedly raised transaminases with no liver explanation should prompt creatine kinase because muscle releases AST and ALT.

Weakness with areflexia progressing over days suggests Guillain-Barré syndrome, while bladder change, sensory level or brisk reflexes suggests spinal cord disease.

Children with dystrophinopathy have anaesthetic-associated rhabdomyolysis and hyperkalaemia risk; avoid succinylcholine and ensure specialist anaesthetic planning.

Investigation priorities

01
First-line serum creatine kinaseFirst stepFirst line

Detect muscle-fibre injury in a child with objective weakness, Gowers manoeuvre or delayed motor milestones.

Management branches

LocaliseConfirm genuine weakness

A child has delayed motor skills, falls or loss of function.

  1. Observe play, floor rise, run and stairs before formal power, reflex and sensory examination.
  2. Screen bulbar, respiratory, cardiac and bladder symptoms to identify emergency localisation.
  3. Request creatine kinase promptly for objective proximal weakness or Gowers manoeuvre.

Key medicines

Prednisolone in DuchenneA common specialist daily regimen is 0.75 mg/kg orally once daily, with dose or intermittent schedule adjusted to response and adverse effects; provide a written steroid sick-day and perioperative plan and never stop abruptly.Monitor weight, height, blood pressure, behaviour, glucose, cataract, infection, puberty, bone strength and adrenal suppression; give stress dosing during significant illness or surgery as directed.
Deflazacort in DuchenneA common specialist daily regimen is 0.9 mg/kg orally once daily, adjusted by the neuromuscular team for benefit, growth and toxicity, with the same adrenal emergency precautions as other chronic glucocorticoids.Cushingoid effects, cataract, growth and pubertal suppression, hypertension, infection, osteoporosis and adrenal crisis remain important despite differing weight effects from prednisolone.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG127 Neurological RecognitionReferral for motor regression, weakness and creatine kinase testing in boys.
  • NHS Muscular Dystrophy OverviewPresentation, diagnosis and multidisciplinary management.
  • Muscular Dystrophy UK DuchenneUK family information on diagnosis, progression and care.
  • DMD Care UK StandardsUK consensus care pathways for Duchenne multidisciplinary management.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom